BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37587323)

  • 1. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
    Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
    Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.
    Carrieri P; Carrat F; Di Beo V; Bourlière M; Barré T; De Ledinghen V; Pageaux GP; Bureau M; Cagnot C; Dorival C; Delarocque-Astagneau E; Marcellin F; Pol S; Fontaine H; Protopopescu C;
    JHEP Rep; 2022 Jun; 4(6):100481. PubMed ID: 35514789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
    Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
    Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
    Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
    BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV).
    Abbas M; Patrizia C; Fabienne M; Marc B; Lucia P; Fabrice C; Martin D; Camelia P
    Qual Life Res; 2024 Apr; ():. PubMed ID: 38580786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).
    Santos M; Protopopescu C; Delarocque-Astagneau E; Bourlière M; Petrov-Sanchez V; Di Beo V; Larrey D; Baudoin M; Dorival C; Bureau M; Fontaine H; Carrat F; Marcellin F; Pol S; Carrieri P;
    Liver Int; 2022 Jan; 42(1):38-49. PubMed ID: 34520614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
    HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France.
    Djaogol T; Fontaine H; Baudoin M; Protopopescu C; Marcellin F; Dorival C; Simony M; Petrov-Sanchez V; Bourlière M; Delarocque-Astagneau E; Pol S; Carrat F; Carrieri P;
    Liver Int; 2021 Oct; 41(10):2328-2340. PubMed ID: 33590608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in hepatitis C virus-cured vs. hepatitis C virus-uninfected people with HIV.
    Requena MB; Grabar S; Lanoy E; Pialoux G; Billaud E; Duvivier C; Merle P; Piroth L; Tattevin P; Salmon D; Weiss L; Costagliola D; Lacombe K
    AIDS; 2023 Jul; 37(8):1297-1306. PubMed ID: 37070541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
    Pageaux GP; Nzinga CL; Ganne N; Samuel D; Dorival C; Zoulim F; Cagnot C; Decaens T; Thabut D; Asselah T; Mathurin P; Habersetzer F; Bronowicki JP; Guyader D; Rosa I; Leroy V; Chazouilleres O; de Ledinghen V; Bourliere M; Causse X; Cales P; Metivier S; Loustaud-Ratti V; Riachi G; Alric L; Gelu-Simeon M; Minello A; Gournay J; Geist C; Tran A; Abergel A; Portal I; d'Alteroche L; Raffi F; Fontaine H; Carrat F; Pol S;
    BMC Infect Dis; 2022 Jan; 22(1):94. PubMed ID: 35086481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
    Azzi J; Dorival C; Cagnot C; Fontaine H; Lusivika-Nzinga C; Leroy V; De Ledinghen V; Tran A; Zoulim F; Alric L; Gournay J; Bronowicki JP; Decaens T; Riachi G; Mikhail N; Soliman R; Shiha G; Pol S; Carrat F; Ganne-Carrié N;
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101923. PubMed ID: 35405354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
    de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
    J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
    Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
    Tacke F; Klinker H; Boeker KHW; Merle U; Link R; Buggisch P; Hüppe D; Cornberg M; Sarrazin C; Wedemeyer H; Berg T; Mauss S;
    Hepatol Commun; 2022 Sep; 6(9):2488-2495. PubMed ID: 35666055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
    Costa M; Rojas TR; Lacoste D; Villes V; Aumaitre H; Protopopescu C; Yaya I; Wittkop L; Krause J; Salmon-Céron D; Marcellin F; Sogni P; Carrieri MP;
    Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1508-1517. PubMed ID: 31094856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ITTREAT (Integrated Community Test - Stage - TREAT) Hepatitis C service for people who use drugs: Real-world outcomes.
    O'Sullivan M; Jones AM; Gage H; Jordan J; MacPepple E; Williams H; Verma S
    Liver Int; 2020 May; 40(5):1021-1031. PubMed ID: 32048798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.